223 related articles for article (PubMed ID: 24747809)
1. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
2. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS.
Xiong S; Yu B; Wu J; Li H; Lee RJ
Biomed Pharmacother; 2011 Feb; 65(1):2-8. PubMed ID: 21177069
[TBL] [Abstract][Full Text] [Related]
3. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model.
Pan XQ; Lee RJ
Anticancer Res; 2005; 25(1A):343-6. PubMed ID: 15816557
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
6. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
Wang Y; Liu F; Wang Q; Xiang H; Jin H; Li H; Mao S
Int J Pharm; 2017 Aug; 529(1-2):531-542. PubMed ID: 28583331
[TBL] [Abstract][Full Text] [Related]
7. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
[TBL] [Abstract][Full Text] [Related]
8. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
[TBL] [Abstract][Full Text] [Related]
9. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
11. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.
Goemans BF; Zwaan CM; Reinhardt D; Gibson BE; Hählen K; Kaspers GJ
Haematologica; 2006 Nov; 91(11):1573-4. PubMed ID: 17043024
[TBL] [Abstract][Full Text] [Related]
14. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
15. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
16. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
19. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
[TBL] [Abstract][Full Text] [Related]
20. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
Hui YF; Cortes JE
Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]